Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Jefferies 2019 London Healthcare Conference
20 slides from Adma Biologics's conference presentation, Nov 19, 2019
Slide 1: Jefferies 2019 London Healthcare Conference
WWW.ADMABIOLOGICS.COM ADMA BIOLOGICS ADMA Biologics , GROUNDBREAKING IMMUNOTECHNOLOGY, ONE CONNECTION AT A TIME Jefferies 2019 London Healthcare Conference November 20, 2019 ‘Nasdaq: ADMA,
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘his presentation contains "Yoruarooking statements,"pursuant tothe safeharbr provisions of the Private Secures Ligation Reform Act of 1995, about ADMA Boogis, Ino. Cue," "our" or the ‘Company’) including, uthout limitation, statements that may predict, forecast, indicate,
Slide 3: Who We Are
CE WHO WE ARE \ Gale ADMA Biologicsis a vertically integrated commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products forthe immune-compromised and other patients at risk for infection. Itis our devotion to these underserved populat
Slide 4: Corporate Highlights
CORPORATE HIGHLIGHTS THREE APPROVED AND MARKETED PRODUCTS — MULTI-FACETED REVENUE PLATFORM 1@ months of 2019 “Generated $17M in revenues for full year 2018 ancl $17.3M for first “BIVIGAM and ASCENIV now commercially available in the U.S. *Revenues derived from commercial products, manufacturing inte
Slide 5: Blood & Plasma Composition
BLOOD & PLASMA COMPOSITION 4 Blood Contains: Plasma, Red Cells, White Cells and Platelets Plasma Contains: Protein and Water Plasma Proteins Contain Many Therapeutic Benefits: + Intravenous immunoglobulin (IVIG) is made from a key therapeutic protein in plasma: Immunoglobulin (IgG) + IgG = naturally
Slide 6: Plasma Products Portfolio & Pipeline
ae rl OSIeS.COM ADMA BIOLOGICS Plasma Products Portfolior& Pipeline sc evisam wo (HUMAN, 10% LOUIO ‘Nasdaq: ADMA,
Slide 7: Growth Drivers: Plasma IG Market Is Sizeable & Growing
GROWTH DRIVERS: PLASMA IG MARKET IS SIZEABLE & GROWING GEaey IMMUNE GLOBULIN (IG or IVIG) is a pooled plasma product ~$6 Billion U.S. Immune Globulin (1G) Market from healthy plasma donors, containing a range of polyclonal antibodies against common pathogens US te wearer (2010.17) Billions of dollar
Slide 8: IG Is Widely Used and Reimbursed
IG IS WIDELY USED AND REIMBURSED FDA-Approved Uses” Possible Additional Reimbursed Evidence-Based Uses Primary immunodeficiency (PI) Acquired red cell aplasia Multiple myeloma Rasmussen's syndrome Multifocal motor neuropathy Bone marrow transplantation Myasthenia gravis Fete transplant from liver 7
Slide 9: Commercial Products: Brands in an Expanding IG Market
COMMERCIAL PRODUCTS: 3 BRANDS IN AN EXPANDING IG MARKET ASCENIV ASCENIV™ (immune Globulin Intravenous - stra, Human) FDA-APPROVED PROTECTION AGAINST SERIOUS INFECTIONS “Indicated for the treatment af patients with Pl * Contains a wide spectrum of polyclonal antibodies ‘against endemic pathogens * Me
Slide 10: PI Is a Significant Market Opportunity for ADMA
PLIS A SIGNIFICANT MARKET OPPORTUNITY FOR ADMA ~250,000 Pl PATIENTS in the US aS Population ~50% are treated with 1G Common'VariableImmune 1 25,000ta1in5.000 --~2,000ta5,00Dpatients Deficiency (VID) (7,000-14,000 patients} Severe Combinedimmune __Newediagnoses of-10Qcases 500-1,000patientson MIG THE
Slide 11: ADMA Is an Advocate for the PI Patient
ADMA IS AN ADVOCATE FOR THE PI PATIENT Different Patient Types Present with Different Risks for infection Risk Factors for Infection in PI + Type and severity of immune deficiency + Age + Impaired pulmonary function ¥ Bronchiectasis ¥ Asthma ¥ History of respiratory infection/environmental condition
Slide 12: Discover the Novelty of ADMA's Patented Immunotechnology
DISCOVER THE NOVELTY OF ADMA’S PATENTED IMMUNOTECHNOLOGY USED TO MANUFACTURE ASCENIV™ 1"
Slide 13: ADMA Pipeline
ADMA PIPELINE Potential Target Populations for ASCENIV™ As previously disclosed, we believe the FDA approval of ASCENIV™ better positions ADMA to further its mission to evaluate ASCENIV™ in irmmune-compromised patients infected with or at-risk for Respiratory Syncytial Virus (RSV) infection + HSCT/B
Slide 14: Potential Follow-On Specialty Plasma Products
cGMP Come Potential Follow-On Specialty Plasma Products By leveraging ADMA's IP, know-how and expertise, we may seek ta expand aur product portfolio with additional specialty IG products by building upon aur core cornpetency of identifying high-titer plasma donors and plasma products manufacturing e
Slide 15: Milestones, Corporate and Financial Information
WWW.ADMABIOLOGICS.COM ADMA Milestones, Corporate Fighl and Financial Information at Nasdaq: ADMA,
Slide 16: Recent Milestones & Future Objectives
RECENT MILESTONES & FUTURE OBJECTIVES \ ST RECENTLY COMPLETED FUTURE & ONGOING OBJECTIVES ¥ Relaunched BIVIGAM® with first commercial sales in the U.S. v Obtained FDA approval for BIVIGAM® PAS 2 biseidua peieuual clade v First Commercial Sales of ASCENIV™ development pipeline consisting of additiona
Slide 17: Financial Information
FINANCIAL INFORMATION Financial Summa 430/19 Results Cash and cash equivalents $48,0M Total assets $137.8M Total liabilities $101.7M Total stockholders’ equity $36.1M Revenue (9 months) $173M Common stock outstanding 593M Fully dilutec! common stock outstanding 67.1M *Adcitional funding commitment o
Slide 18: Experienced Management Team and Board of Directors
EXPERIENCED MANAGEMENT TEAM AND BOARD OF DIRECTORS Fame | SELECTED CURRENT OR PAST AFFLIATIONS Adam Grossman ‘ yy ae lial 2 G CEO aoirector edimmine GENESIS. ioe Brian Lene, CPA Ecectie vice Presicent; Chef hols BioSNJ’ Financial Officer James Mond, MD, PRD é ro Executive icePresidert Chiet we f Sci
Slide 19: FDA Licensed Facility
FDA LICENSED FACILITY PROCESS VALIDATION THREE COMMERCIAL PRODUCTS PIPELINE USING IMMUNOTECHNOLOGY IP CONTRACT MANUFACTURING & TESTING PLASMA COLLECTION VERTICAL INTEGRATION + CURRENT CONTRACT FOR HYPERIMMUNE ABILITY TO SUPPLY A PORTION OF THE GLOBUFINTEMO INTERNAL NEEDS AND SELL TO 34 PARTIES + FUL
Slide 20: Thank You
AD MABIOLOGICS.COM Thank You ‘Nasdaq: ADMA, _ eee
ADMA Biologics — Jefferies 2019 London Healthcare Conference on 6ix